nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—OPRK1—Progesterone—uterine cancer	0.205	0.325	CbGbCtD
Loperamide—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0885	0.141	CbGbCtD
Loperamide—CYP2C8—Progesterone—uterine cancer	0.0586	0.0932	CbGbCtD
Loperamide—ABCB1—Progesterone—uterine cancer	0.0397	0.0631	CbGbCtD
Loperamide—CYP2D6—Progesterone—uterine cancer	0.0374	0.0594	CbGbCtD
Loperamide—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0359	0.0571	CbGbCtD
Loperamide—ABCB1—Dactinomycin—uterine cancer	0.0315	0.05	CbGbCtD
Loperamide—CYP2C8—Etoposide—uterine cancer	0.0262	0.0417	CbGbCtD
Loperamide—CYP3A4—Progesterone—uterine cancer	0.0238	0.0378	CbGbCtD
Loperamide—CYP2B6—Doxorubicin—uterine cancer	0.0236	0.0376	CbGbCtD
Loperamide—ABCB1—Etoposide—uterine cancer	0.0178	0.0282	CbGbCtD
Loperamide—ABCB1—Doxorubicin—uterine cancer	0.0121	0.0193	CbGbCtD
Loperamide—CYP2D6—Doxorubicin—uterine cancer	0.0114	0.0181	CbGbCtD
Loperamide—CYP3A4—Etoposide—uterine cancer	0.0106	0.0169	CbGbCtD
Loperamide—CYP3A4—Doxorubicin—uterine cancer	0.00725	0.0115	CbGbCtD
Loperamide—CALM2—semen—uterine cancer	0.00624	0.0654	CbGeAlD
Loperamide—CALM1—semen—uterine cancer	0.00621	0.0651	CbGeAlD
Loperamide—CALM2—oviduct—uterine cancer	0.00458	0.048	CbGeAlD
Loperamide—Abdominal bloating—Progesterone—uterine cancer	0.00454	0.0449	CcSEcCtD
Loperamide—Abdominal bloating—Medroxyprogesterone Acetate—uterine cancer	0.00412	0.0407	CcSEcCtD
Loperamide—POMC—renal system—uterine cancer	0.0039	0.0409	CbGeAlD
Loperamide—POMC—female reproductive system—uterine cancer	0.00313	0.0328	CbGeAlD
Loperamide—CALM2—artery—uterine cancer	0.00303	0.0318	CbGeAlD
Loperamide—CALM1—artery—uterine cancer	0.00302	0.0316	CbGeAlD
Loperamide—POMC—female gonad—uterine cancer	0.00285	0.0298	CbGeAlD
Loperamide—POMC—vagina—uterine cancer	0.00283	0.0296	CbGeAlD
Loperamide—CALM2—exocrine gland—uterine cancer	0.00264	0.0277	CbGeAlD
Loperamide—CALM1—exocrine gland—uterine cancer	0.00263	0.0276	CbGeAlD
Loperamide—OPRD1—renal system—uterine cancer	0.00215	0.0226	CbGeAlD
Loperamide—Depressed level of consciousness—Progesterone—uterine cancer	0.00209	0.0206	CcSEcCtD
Loperamide—CALM3—myometrium—uterine cancer	0.00187	0.0195	CbGeAlD
Loperamide—OPRK1—female reproductive system—uterine cancer	0.00165	0.0173	CbGeAlD
Loperamide—Anaphylactoid reaction—Progesterone—uterine cancer	0.00162	0.016	CcSEcCtD
Loperamide—Bullous eruption—Epirubicin—uterine cancer	0.00157	0.0155	CcSEcCtD
Loperamide—Anaphylactoid reaction—Medroxyprogesterone Acetate—uterine cancer	0.00147	0.0145	CcSEcCtD
Loperamide—CALM2—myometrium—uterine cancer	0.00146	0.0153	CbGeAlD
Loperamide—CALM1—myometrium—uterine cancer	0.00146	0.0153	CbGeAlD
Loperamide—Bullous eruption—Doxorubicin—uterine cancer	0.00145	0.0143	CcSEcCtD
Loperamide—CALM3—uterine cervix—uterine cancer	0.00145	0.0152	CbGeAlD
Loperamide—CALM3—smooth muscle tissue—uterine cancer	0.00141	0.0148	CbGeAlD
Loperamide—CALM3—decidua—uterine cancer	0.00138	0.0145	CbGeAlD
Loperamide—Abdominal distension—Progesterone—uterine cancer	0.00137	0.0135	CcSEcCtD
Loperamide—Urinary retention—Medroxyprogesterone Acetate—uterine cancer	0.00135	0.0134	CcSEcCtD
Loperamide—CALM3—endometrium—uterine cancer	0.00131	0.0138	CbGeAlD
Loperamide—CALM3—mammalian vulva—uterine cancer	0.00127	0.0133	CbGeAlD
Loperamide—Abdominal distension—Medroxyprogesterone Acetate—uterine cancer	0.00124	0.0122	CcSEcCtD
Loperamide—Drowsiness—Progesterone—uterine cancer	0.00121	0.012	CcSEcCtD
Loperamide—CALM3—uterus—uterine cancer	0.00121	0.0127	CbGeAlD
Loperamide—CALM2—epithelium—uterine cancer	0.00115	0.012	CbGeAlD
Loperamide—CALM1—epithelium—uterine cancer	0.00114	0.012	CbGeAlD
Loperamide—CALM2—uterine cervix—uterine cancer	0.00114	0.0119	CbGeAlD
Loperamide—CALM1—uterine cervix—uterine cancer	0.00113	0.0119	CbGeAlD
Loperamide—Clotrimazole—CYP11A1—uterine cancer	0.00113	0.245	CrCbGaD
Loperamide—CALM2—smooth muscle tissue—uterine cancer	0.00111	0.0116	CbGeAlD
Loperamide—CALM1—smooth muscle tissue—uterine cancer	0.0011	0.0116	CbGeAlD
Loperamide—Drowsiness—Medroxyprogesterone Acetate—uterine cancer	0.0011	0.0108	CcSEcCtD
Loperamide—CALM2—decidua—uterine cancer	0.00109	0.0114	CbGeAlD
Loperamide—CALM1—decidua—uterine cancer	0.00108	0.0113	CbGeAlD
Loperamide—Urinary tract disorder—Progesterone—uterine cancer	0.00107	0.0106	CcSEcCtD
Loperamide—CALM2—renal system—uterine cancer	0.00107	0.0112	CbGeAlD
Loperamide—Urethral disorder—Progesterone—uterine cancer	0.00107	0.0105	CcSEcCtD
Loperamide—CALM1—renal system—uterine cancer	0.00106	0.0111	CbGeAlD
Loperamide—CALM2—endometrium—uterine cancer	0.00103	0.0108	CbGeAlD
Loperamide—Erythema multiforme—Progesterone—uterine cancer	0.00103	0.0102	CcSEcCtD
Loperamide—CALM1—endometrium—uterine cancer	0.00103	0.0108	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Dactinomycin—uterine cancer	0.001	0.00988	CcSEcCtD
Loperamide—CALM2—mammalian vulva—uterine cancer	0.000997	0.0104	CbGeAlD
Loperamide—CALM1—mammalian vulva—uterine cancer	0.000993	0.0104	CbGeAlD
Loperamide—CALM3—female gonad—uterine cancer	0.00099	0.0104	CbGeAlD
Loperamide—CALM3—vagina—uterine cancer	0.000984	0.0103	CbGeAlD
Loperamide—Immune system disorder—Progesterone—uterine cancer	0.000981	0.0097	CcSEcCtD
Loperamide—Urinary tract disorder—Medroxyprogesterone Acetate—uterine cancer	0.000972	0.00961	CcSEcCtD
Loperamide—Urethral disorder—Medroxyprogesterone Acetate—uterine cancer	0.000965	0.00954	CcSEcCtD
Loperamide—CALM2—uterus—uterine cancer	0.00095	0.00995	CbGeAlD
Loperamide—CALM1—uterus—uterine cancer	0.000946	0.00991	CbGeAlD
Loperamide—Flatulence—Progesterone—uterine cancer	0.000932	0.00921	CcSEcCtD
Loperamide—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.000931	0.0092	CcSEcCtD
Loperamide—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000889	0.00879	CcSEcCtD
Loperamide—CYP2C8—renal system—uterine cancer	0.000884	0.00926	CbGeAlD
Loperamide—Ileus—Epirubicin—uterine cancer	0.000877	0.00866	CcSEcCtD
Loperamide—Angioedema—Progesterone—uterine cancer	0.000864	0.00854	CcSEcCtD
Loperamide—CYP2C8—endometrium—uterine cancer	0.000854	0.00895	CbGeAlD
Loperamide—CALM2—female reproductive system—uterine cancer	0.000854	0.00895	CbGeAlD
Loperamide—CALM1—female reproductive system—uterine cancer	0.00085	0.00891	CbGeAlD
Loperamide—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	0.000848	0.00838	CcSEcCtD
Loperamide—Flatulence—Medroxyprogesterone Acetate—uterine cancer	0.000845	0.00834	CcSEcCtD
Loperamide—Loss of consciousness—Progesterone—uterine cancer	0.000831	0.00821	CcSEcCtD
Loperamide—Anaphylactoid reaction—Etoposide—uterine cancer	0.00083	0.0082	CcSEcCtD
Loperamide—Ileus—Doxorubicin—uterine cancer	0.000811	0.00801	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.0008	0.0079	CcSEcCtD
Loperamide—Discomfort—Progesterone—uterine cancer	0.000796	0.00786	CcSEcCtD
Loperamide—CYP2B6—renal system—uterine cancer	0.000793	0.0083	CbGeAlD
Loperamide—Toremifene—ESR1—uterine cancer	0.000793	0.172	CrCbGaD
Loperamide—Dry mouth—Progesterone—uterine cancer	0.000788	0.00778	CcSEcCtD
Loperamide—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.000783	0.00774	CcSEcCtD
Loperamide—CALM2—female gonad—uterine cancer	0.000777	0.00814	CbGeAlD
Loperamide—CALM1—female gonad—uterine cancer	0.000774	0.0081	CbGeAlD
Loperamide—CALM2—vagina—uterine cancer	0.000772	0.00809	CbGeAlD
Loperamide—Anaphylactic shock—Progesterone—uterine cancer	0.000772	0.00763	CcSEcCtD
Loperamide—CALM1—vagina—uterine cancer	0.000769	0.00805	CbGeAlD
Loperamide—Nervous system disorder—Progesterone—uterine cancer	0.000757	0.00748	CcSEcCtD
Loperamide—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	0.000753	0.00744	CcSEcCtD
Loperamide—Skin disorder—Progesterone—uterine cancer	0.00075	0.00741	CcSEcCtD
Loperamide—Erythema multiforme—Dactinomycin—uterine cancer	0.000726	0.00717	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000725	0.00716	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Etoposide—uterine cancer	0.000723	0.00715	CcSEcCtD
Loperamide—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000721	0.00712	CcSEcCtD
Loperamide—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.000714	0.00705	CcSEcCtD
Loperamide—CYP2C8—female reproductive system—uterine cancer	0.000708	0.00741	CbGeAlD
Loperamide—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.000699	0.00691	CcSEcCtD
Loperamide—Somnolence—Progesterone—uterine cancer	0.000686	0.00678	CcSEcCtD
Loperamide—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000686	0.00678	CcSEcCtD
Loperamide—Dyspepsia—Progesterone—uterine cancer	0.000679	0.00671	CcSEcCtD
Loperamide—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000679	0.00671	CcSEcCtD
Loperamide—Gastrointestinal disorder—Progesterone—uterine cancer	0.000666	0.00658	CcSEcCtD
Loperamide—Fatigue—Progesterone—uterine cancer	0.000666	0.00658	CcSEcCtD
Loperamide—Constipation—Progesterone—uterine cancer	0.00066	0.00652	CcSEcCtD
Loperamide—CYP2C8—vagina—uterine cancer	0.00064	0.00671	CbGeAlD
Loperamide—CALM3—lymph node—uterine cancer	0.000636	0.00666	CbGeAlD
Loperamide—CYP2B6—female reproductive system—uterine cancer	0.000635	0.00665	CbGeAlD
Loperamide—Gastrointestinal pain—Progesterone—uterine cancer	0.000631	0.00624	CcSEcCtD
Loperamide—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000622	0.00614	CcSEcCtD
Loperamide—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000616	0.00608	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000614	0.00606	CcSEcCtD
Loperamide—Urticaria—Progesterone—uterine cancer	0.000613	0.00606	CcSEcCtD
Loperamide—Abdominal pain—Progesterone—uterine cancer	0.00061	0.00603	CcSEcCtD
Loperamide—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000604	0.00597	CcSEcCtD
Loperamide—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000603	0.00596	CcSEcCtD
Loperamide—CYP3A4—renal system—uterine cancer	0.000599	0.00627	CbGeAlD
Loperamide—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000598	0.00591	CcSEcCtD
Loperamide—CYP2D6—renal system—uterine cancer	0.000589	0.00617	CbGeAlD
Loperamide—ABCB1—myometrium—uterine cancer	0.000582	0.0061	CbGeAlD
Loperamide—Levomethadyl Acetate—CYP19A1—uterine cancer	0.000582	0.127	CrCbGaD
Loperamide—Clotrimazole—CYP19A1—uterine cancer	0.000582	0.127	CrCbGaD
Loperamide—CYP2B6—vagina—uterine cancer	0.000574	0.00602	CbGeAlD
Loperamide—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000572	0.00565	CcSEcCtD
Loperamide—Hypersensitivity—Progesterone—uterine cancer	0.000569	0.00562	CcSEcCtD
Loperamide—Discomfort—Dactinomycin—uterine cancer	0.000562	0.00556	CcSEcCtD
Loperamide—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000556	0.00549	CcSEcCtD
Loperamide—Asthenia—Progesterone—uterine cancer	0.000554	0.00547	CcSEcCtD
Loperamide—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000553	0.00546	CcSEcCtD
Loperamide—Urinary tract disorder—Etoposide—uterine cancer	0.000549	0.00542	CcSEcCtD
Loperamide—Pruritus—Progesterone—uterine cancer	0.000546	0.0054	CcSEcCtD
Loperamide—Urethral disorder—Etoposide—uterine cancer	0.000545	0.00538	CcSEcCtD
Loperamide—Diarrhoea—Progesterone—uterine cancer	0.000528	0.00522	CcSEcCtD
Loperamide—Erythema multiforme—Etoposide—uterine cancer	0.000526	0.00519	CcSEcCtD
Loperamide—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000515	0.00509	CcSEcCtD
Loperamide—Tamoxifen—ESR2—uterine cancer	0.000514	0.112	CrCbGaD
Loperamide—Dizziness—Progesterone—uterine cancer	0.00051	0.00504	CcSEcCtD
Loperamide—Immune system disorder—Etoposide—uterine cancer	0.000502	0.00496	CcSEcCtD
Loperamide—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000502	0.00496	CcSEcCtD
Loperamide—CALM2—lymph node—uterine cancer	0.0005	0.00523	CbGeAlD
Loperamide—CALM1—lymph node—uterine cancer	0.000497	0.00521	CbGeAlD
Loperamide—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000495	0.00489	CcSEcCtD
Loperamide—Vomiting—Progesterone—uterine cancer	0.000491	0.00485	CcSEcCtD
Loperamide—Rash—Progesterone—uterine cancer	0.000487	0.00481	CcSEcCtD
Loperamide—Dermatitis—Progesterone—uterine cancer	0.000486	0.0048	CcSEcCtD
Loperamide—Headache—Progesterone—uterine cancer	0.000484	0.00478	CcSEcCtD
Loperamide—CYP3A4—female reproductive system—uterine cancer	0.000479	0.00502	CbGeAlD
Loperamide—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000479	0.00473	CcSEcCtD
Loperamide—CYP2D6—female reproductive system—uterine cancer	0.000472	0.00494	CbGeAlD
Loperamide—Dermatitis bullous—Epirubicin—uterine cancer	0.000471	0.00466	CcSEcCtD
Loperamide—Fatigue—Dactinomycin—uterine cancer	0.00047	0.00465	CcSEcCtD
Loperamide—Anaphylactoid reaction—Epirubicin—uterine cancer	0.000465	0.0046	CcSEcCtD
Loperamide—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000463	0.00457	CcSEcCtD
Loperamide—Nausea—Progesterone—uterine cancer	0.000459	0.00453	CcSEcCtD
Loperamide—ABCB1—epithelium—uterine cancer	0.000457	0.00479	CbGeAlD
Loperamide—ABCB1—uterine cervix—uterine cancer	0.000453	0.00474	CbGeAlD
Loperamide—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000446	0.00441	CcSEcCtD
Loperamide—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000445	0.00439	CcSEcCtD
Loperamide—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000441	0.00436	CcSEcCtD
Loperamide—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000441	0.00435	CcSEcCtD
Loperamide—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000438	0.00433	CcSEcCtD
Loperamide—Dermatitis bullous—Doxorubicin—uterine cancer	0.000436	0.00431	CcSEcCtD
Loperamide—ABCB1—decidua—uterine cancer	0.000432	0.00452	CbGeAlD
Loperamide—Abdominal pain—Dactinomycin—uterine cancer	0.000431	0.00426	CcSEcCtD
Loperamide—Anaphylactoid reaction—Doxorubicin—uterine cancer	0.000431	0.00425	CcSEcCtD
Loperamide—CYP2D6—female gonad—uterine cancer	0.000429	0.0045	CbGeAlD
Loperamide—Loss of consciousness—Etoposide—uterine cancer	0.000425	0.0042	CcSEcCtD
Loperamide—ABCB1—renal system—uterine cancer	0.000424	0.00444	CbGeAlD
Loperamide—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000415	0.00411	CcSEcCtD
Loperamide—Abdominal pain upper—Epirubicin—uterine cancer	0.000411	0.00406	CcSEcCtD
Loperamide—ABCB1—endometrium—uterine cancer	0.00041	0.00429	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000409	0.00404	CcSEcCtD
Loperamide—Discomfort—Etoposide—uterine cancer	0.000407	0.00402	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000406	0.00401	CcSEcCtD
Loperamide—Hypersensitivity—Dactinomycin—uterine cancer	0.000402	0.00397	CcSEcCtD
Loperamide—ABCB1—mammalian vulva—uterine cancer	0.000396	0.00415	CbGeAlD
Loperamide—Anaphylactic shock—Etoposide—uterine cancer	0.000395	0.0039	CcSEcCtD
Loperamide—Abdominal distension—Epirubicin—uterine cancer	0.000392	0.00387	CcSEcCtD
Loperamide—Asthenia—Dactinomycin—uterine cancer	0.000391	0.00387	CcSEcCtD
Loperamide—Skin disorder—Etoposide—uterine cancer	0.000384	0.00379	CcSEcCtD
Loperamide—Abdominal pain upper—Doxorubicin—uterine cancer	0.000381	0.00376	CcSEcCtD
Loperamide—ABCB1—uterus—uterine cancer	0.000378	0.00395	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000375	0.00371	CcSEcCtD
Loperamide—Diarrhoea—Dactinomycin—uterine cancer	0.000373	0.00369	CcSEcCtD
Loperamide—Abdominal distension—Doxorubicin—uterine cancer	0.000363	0.00358	CcSEcCtD
Loperamide—Somnolence—Etoposide—uterine cancer	0.000351	0.00347	CcSEcCtD
Loperamide—Drowsiness—Epirubicin—uterine cancer	0.000347	0.00343	CcSEcCtD
Loperamide—Vomiting—Dactinomycin—uterine cancer	0.000347	0.00343	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000344	0.0034	CcSEcCtD
Loperamide—Tamoxifen—CYP19A1—uterine cancer	0.000344	0.0748	CrCbGaD
Loperamide—Rash—Dactinomycin—uterine cancer	0.000344	0.0034	CcSEcCtD
Loperamide—Methadone—CYP19A1—uterine cancer	0.000341	0.0742	CrCbGaD
Loperamide—Gastrointestinal disorder—Etoposide—uterine cancer	0.000341	0.00337	CcSEcCtD
Loperamide—Fatigue—Etoposide—uterine cancer	0.00034	0.00336	CcSEcCtD
Loperamide—ABCB1—female reproductive system—uterine cancer	0.000339	0.00356	CbGeAlD
Loperamide—Constipation—Etoposide—uterine cancer	0.000338	0.00334	CcSEcCtD
Loperamide—Nausea—Dactinomycin—uterine cancer	0.000324	0.0032	CcSEcCtD
Loperamide—Gastrointestinal pain—Etoposide—uterine cancer	0.000323	0.00319	CcSEcCtD
Loperamide—Drowsiness—Doxorubicin—uterine cancer	0.000321	0.00317	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000318	0.00315	CcSEcCtD
Loperamide—Tamoxifen—ESR1—uterine cancer	0.000317	0.0689	CrCbGaD
Loperamide—Urticaria—Etoposide—uterine cancer	0.000314	0.0031	CcSEcCtD
Loperamide—Abdominal pain—Etoposide—uterine cancer	0.000312	0.00308	CcSEcCtD
Loperamide—ABCB1—female gonad—uterine cancer	0.000309	0.00323	CbGeAlD
Loperamide—Urinary tract disorder—Epirubicin—uterine cancer	0.000308	0.00304	CcSEcCtD
Loperamide—ABCB1—vagina—uterine cancer	0.000307	0.00322	CbGeAlD
Loperamide—Urethral disorder—Epirubicin—uterine cancer	0.000305	0.00302	CcSEcCtD
Loperamide—Erythema multiforme—Epirubicin—uterine cancer	0.000295	0.00291	CcSEcCtD
Loperamide—Hypersensitivity—Etoposide—uterine cancer	0.000291	0.00287	CcSEcCtD
Loperamide—Urinary tract disorder—Doxorubicin—uterine cancer	0.000285	0.00281	CcSEcCtD
Loperamide—Asthenia—Etoposide—uterine cancer	0.000283	0.0028	CcSEcCtD
Loperamide—Urethral disorder—Doxorubicin—uterine cancer	0.000283	0.00279	CcSEcCtD
Loperamide—Immune system disorder—Epirubicin—uterine cancer	0.000281	0.00278	CcSEcCtD
Loperamide—Pruritus—Etoposide—uterine cancer	0.000279	0.00276	CcSEcCtD
Loperamide—Erythema multiforme—Doxorubicin—uterine cancer	0.000273	0.00269	CcSEcCtD
Loperamide—Diarrhoea—Etoposide—uterine cancer	0.00027	0.00267	CcSEcCtD
Loperamide—Flatulence—Epirubicin—uterine cancer	0.000267	0.00264	CcSEcCtD
Loperamide—Dizziness—Etoposide—uterine cancer	0.000261	0.00258	CcSEcCtD
Loperamide—Immune system disorder—Doxorubicin—uterine cancer	0.00026	0.00257	CcSEcCtD
Loperamide—Vomiting—Etoposide—uterine cancer	0.000251	0.00248	CcSEcCtD
Loperamide—Rash—Etoposide—uterine cancer	0.000249	0.00246	CcSEcCtD
Loperamide—Dermatitis—Etoposide—uterine cancer	0.000249	0.00246	CcSEcCtD
Loperamide—Headache—Etoposide—uterine cancer	0.000247	0.00244	CcSEcCtD
Loperamide—Flatulence—Doxorubicin—uterine cancer	0.000247	0.00244	CcSEcCtD
Loperamide—Loss of consciousness—Epirubicin—uterine cancer	0.000238	0.00236	CcSEcCtD
Loperamide—Nausea—Etoposide—uterine cancer	0.000235	0.00232	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000229	0.00227	CcSEcCtD
Loperamide—Discomfort—Epirubicin—uterine cancer	0.000228	0.00225	CcSEcCtD
Loperamide—Dry mouth—Epirubicin—uterine cancer	0.000226	0.00223	CcSEcCtD
Loperamide—Anaphylactic shock—Epirubicin—uterine cancer	0.000221	0.00219	CcSEcCtD
Loperamide—Loss of consciousness—Doxorubicin—uterine cancer	0.000221	0.00218	CcSEcCtD
Loperamide—Nervous system disorder—Epirubicin—uterine cancer	0.000217	0.00214	CcSEcCtD
Loperamide—Skin disorder—Epirubicin—uterine cancer	0.000215	0.00212	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000212	0.0021	CcSEcCtD
Loperamide—Discomfort—Doxorubicin—uterine cancer	0.000211	0.00209	CcSEcCtD
Loperamide—Dry mouth—Doxorubicin—uterine cancer	0.000209	0.00206	CcSEcCtD
Loperamide—Anaphylactic shock—Doxorubicin—uterine cancer	0.000205	0.00202	CcSEcCtD
Loperamide—Nervous system disorder—Doxorubicin—uterine cancer	0.000201	0.00198	CcSEcCtD
Loperamide—Skin disorder—Doxorubicin—uterine cancer	0.000199	0.00197	CcSEcCtD
Loperamide—ABCB1—lymph node—uterine cancer	0.000199	0.00208	CbGeAlD
Loperamide—Somnolence—Epirubicin—uterine cancer	0.000197	0.00194	CcSEcCtD
Loperamide—Dyspepsia—Epirubicin—uterine cancer	0.000195	0.00193	CcSEcCtD
Loperamide—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000191	0.00189	CcSEcCtD
Loperamide—Fatigue—Epirubicin—uterine cancer	0.000191	0.00189	CcSEcCtD
Loperamide—Constipation—Epirubicin—uterine cancer	0.000189	0.00187	CcSEcCtD
Loperamide—Somnolence—Doxorubicin—uterine cancer	0.000182	0.0018	CcSEcCtD
Loperamide—Gastrointestinal pain—Epirubicin—uterine cancer	0.000181	0.00179	CcSEcCtD
Loperamide—Dyspepsia—Doxorubicin—uterine cancer	0.00018	0.00178	CcSEcCtD
Loperamide—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000177	0.00175	CcSEcCtD
Loperamide—Fatigue—Doxorubicin—uterine cancer	0.000177	0.00174	CcSEcCtD
Loperamide—Urticaria—Epirubicin—uterine cancer	0.000176	0.00174	CcSEcCtD
Loperamide—Constipation—Doxorubicin—uterine cancer	0.000175	0.00173	CcSEcCtD
Loperamide—Abdominal pain—Epirubicin—uterine cancer	0.000175	0.00173	CcSEcCtD
Loperamide—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000167	0.00165	CcSEcCtD
Loperamide—Hypersensitivity—Epirubicin—uterine cancer	0.000163	0.00161	CcSEcCtD
Loperamide—Urticaria—Doxorubicin—uterine cancer	0.000163	0.00161	CcSEcCtD
Loperamide—Abdominal pain—Doxorubicin—uterine cancer	0.000162	0.0016	CcSEcCtD
Loperamide—Asthenia—Epirubicin—uterine cancer	0.000159	0.00157	CcSEcCtD
Loperamide—Pruritus—Epirubicin—uterine cancer	0.000157	0.00155	CcSEcCtD
Loperamide—Diarrhoea—Epirubicin—uterine cancer	0.000151	0.0015	CcSEcCtD
Loperamide—Hypersensitivity—Doxorubicin—uterine cancer	0.000151	0.00149	CcSEcCtD
Loperamide—Asthenia—Doxorubicin—uterine cancer	0.000147	0.00145	CcSEcCtD
Loperamide—Dizziness—Epirubicin—uterine cancer	0.000146	0.00145	CcSEcCtD
Loperamide—Pruritus—Doxorubicin—uterine cancer	0.000145	0.00143	CcSEcCtD
Loperamide—Vomiting—Epirubicin—uterine cancer	0.000141	0.00139	CcSEcCtD
Loperamide—Diarrhoea—Doxorubicin—uterine cancer	0.00014	0.00138	CcSEcCtD
Loperamide—Rash—Epirubicin—uterine cancer	0.00014	0.00138	CcSEcCtD
Loperamide—Dermatitis—Epirubicin—uterine cancer	0.000139	0.00138	CcSEcCtD
Loperamide—Headache—Epirubicin—uterine cancer	0.000139	0.00137	CcSEcCtD
Loperamide—Dizziness—Doxorubicin—uterine cancer	0.000135	0.00134	CcSEcCtD
Loperamide—Nausea—Epirubicin—uterine cancer	0.000131	0.0013	CcSEcCtD
Loperamide—Vomiting—Doxorubicin—uterine cancer	0.00013	0.00129	CcSEcCtD
Loperamide—Rash—Doxorubicin—uterine cancer	0.000129	0.00128	CcSEcCtD
Loperamide—Dermatitis—Doxorubicin—uterine cancer	0.000129	0.00127	CcSEcCtD
Loperamide—Headache—Doxorubicin—uterine cancer	0.000128	0.00127	CcSEcCtD
Loperamide—Nausea—Doxorubicin—uterine cancer	0.000122	0.0012	CcSEcCtD
Loperamide—OPRK1—Signaling Pathways—CDKN1B—uterine cancer	1.19e-05	7.01e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CDKN2B—uterine cancer	1.19e-05	7e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CDKN2B—uterine cancer	1.19e-05	7e-05	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—AKT1—uterine cancer	1.18e-05	6.93e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CYP19A1—uterine cancer	1.17e-05	6.9e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—STK11—uterine cancer	1.17e-05	6.9e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—KRAS—uterine cancer	1.17e-05	6.88e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IGF1R—uterine cancer	1.16e-05	6.8e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IGF1R—uterine cancer	1.16e-05	6.8e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—TP53—uterine cancer	1.16e-05	6.8e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—PIK3CA—uterine cancer	1.16e-05	6.79e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—PIK3CA—uterine cancer	1.16e-05	6.79e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—RRM2—uterine cancer	1.14e-05	6.7e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—KRAS—uterine cancer	1.13e-05	6.66e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—KRAS—uterine cancer	1.13e-05	6.66e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—VEGFA—uterine cancer	1.13e-05	6.65e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CTNNB1—uterine cancer	1.13e-05	6.62e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—KRAS—uterine cancer	1.12e-05	6.61e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SMAD3—uterine cancer	1.12e-05	6.61e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TP53—uterine cancer	1.12e-05	6.57e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TP53—uterine cancer	1.12e-05	6.57e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—NRAS—uterine cancer	1.12e-05	6.56e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—PIK3CA—uterine cancer	1.11e-05	6.51e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—DCN—uterine cancer	1.11e-05	6.5e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—HRAS—uterine cancer	1.1e-05	6.5e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PTEN—uterine cancer	1.1e-05	6.45e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—ERBB2—uterine cancer	1.09e-05	6.39e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—KRAS—uterine cancer	1.09e-05	6.39e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—KRAS—uterine cancer	1.09e-05	6.39e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SMAD3—uterine cancer	1.09e-05	6.39e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SMAD3—uterine cancer	1.09e-05	6.39e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CXCL8—uterine cancer	1.08e-05	6.35e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—PIK3CA—uterine cancer	1.08e-05	6.32e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—MTHFR—uterine cancer	1.07e-05	6.31e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FGFR2—uterine cancer	1.07e-05	6.3e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—AKT1—uterine cancer	1.07e-05	6.29e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—HRAS—uterine cancer	1.07e-05	6.29e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—HRAS—uterine cancer	1.07e-05	6.29e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—EP300—uterine cancer	1.05e-05	6.15e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CXCL8—uterine cancer	1.05e-05	6.15e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CXCL8—uterine cancer	1.05e-05	6.15e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.04e-05	6.13e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—ERBB2—uterine cancer	1.04e-05	6.12e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—PIK3CA—uterine cancer	1.04e-05	6.12e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—PIK3CA—uterine cancer	1.04e-05	6.12e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FGFR2—uterine cancer	1.04e-05	6.1e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FGFR2—uterine cancer	1.04e-05	6.1e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—PIK3CA—uterine cancer	1.03e-05	6.07e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CXCL8—uterine cancer	1.03e-05	6.06e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—HRAS—uterine cancer	1.02e-05	6.03e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—ERBB2—uterine cancer	1.01e-05	5.92e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—ERBB2—uterine cancer	1.01e-05	5.92e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CDKN1B—uterine cancer	1.01e-05	5.92e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—PIK3CA—uterine cancer	9.99e-06	5.87e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—PIK3CA—uterine cancer	9.99e-06	5.87e-05	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—AKT1—uterine cancer	9.96e-06	5.86e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—HRAS—uterine cancer	9.95e-06	5.85e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—VEGFA—uterine cancer	9.91e-06	5.83e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AKR1C3—uterine cancer	9.84e-06	5.79e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—NRAS—uterine cancer	9.79e-06	5.76e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—AKT1—uterine cancer	9.76e-06	5.74e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—CDKN1B—uterine cancer	9.64e-06	5.67e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—HRAS—uterine cancer	9.62e-06	5.66e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—HRAS—uterine cancer	9.62e-06	5.66e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—ERBB2—uterine cancer	9.61e-06	5.65e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—KRAS—uterine cancer	9.61e-06	5.65e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HRAS—uterine cancer	9.55e-06	5.62e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CTNNB1—uterine cancer	9.51e-06	5.59e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	9.46e-06	5.56e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—AKT1—uterine cancer	9.44e-06	5.55e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—AKT1—uterine cancer	9.44e-06	5.55e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—MTHFR—uterine cancer	9.35e-06	5.5e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—CDKN1B—uterine cancer	9.33e-06	5.49e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—CDKN1B—uterine cancer	9.33e-06	5.49e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—ERBB2—uterine cancer	9.3e-06	5.47e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—ERBB2—uterine cancer	9.3e-06	5.47e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PTEN—uterine cancer	9.27e-06	5.45e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HRAS—uterine cancer	9.24e-06	5.43e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HRAS—uterine cancer	9.24e-06	5.43e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ESR1—uterine cancer	9.17e-06	5.39e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—CTNNB1—uterine cancer	9.11e-06	5.36e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—AKT1—uterine cancer	9.05e-06	5.32e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CDKN1B—uterine cancer	8.9e-06	5.24e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—PTEN—uterine cancer	8.88e-06	5.22e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ESR1—uterine cancer	8.87e-06	5.22e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ESR1—uterine cancer	8.87e-06	5.22e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—EP300—uterine cancer	8.84e-06	5.2e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—PIK3CA—uterine cancer	8.83e-06	5.19e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—MTHFR—uterine cancer	8.81e-06	5.18e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—CTNNB1—uterine cancer	8.81e-06	5.18e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—CTNNB1—uterine cancer	8.81e-06	5.18e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—AKT1—uterine cancer	8.78e-06	5.17e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—NRAS—uterine cancer	8.67e-06	5.1e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CDKN1B—uterine cancer	8.61e-06	5.06e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CDKN1B—uterine cancer	8.61e-06	5.06e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—PTEN—uterine cancer	8.59e-06	5.05e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—PTEN—uterine cancer	8.59e-06	5.05e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TP53—uterine cancer	8.54e-06	5.02e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—AKT1—uterine cancer	8.5e-06	5e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—AKT1—uterine cancer	8.5e-06	5e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—EP300—uterine cancer	8.47e-06	4.98e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—AKT1—uterine cancer	8.43e-06	4.96e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—KRAS—uterine cancer	8.42e-06	4.95e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CTNNB1—uterine cancer	8.41e-06	4.95e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—NRAS—uterine cancer	8.38e-06	4.93e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—NRAS—uterine cancer	8.38e-06	4.93e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—VEGFA—uterine cancer	8.37e-06	4.93e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—NRAS—uterine cancer	8.27e-06	4.87e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PTEN—uterine cancer	8.2e-06	4.82e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—EP300—uterine cancer	8.19e-06	4.82e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—EP300—uterine cancer	8.19e-06	4.82e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—HRAS—uterine cancer	8.17e-06	4.8e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—AKT1—uterine cancer	8.16e-06	4.8e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—AKT1—uterine cancer	8.16e-06	4.8e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CTNNB1—uterine cancer	8.13e-06	4.78e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CTNNB1—uterine cancer	8.13e-06	4.78e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCL2—uterine cancer	8.07e-06	4.75e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PTEN—uterine cancer	7.93e-06	4.66e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTEN—uterine cancer	7.93e-06	4.66e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—NRAS—uterine cancer	7.92e-06	4.66e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—EP300—uterine cancer	7.82e-06	4.6e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCL2—uterine cancer	7.81e-06	4.59e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCL2—uterine cancer	7.81e-06	4.59e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PIK3CA—uterine cancer	7.74e-06	4.55e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP19A1—uterine cancer	7.67e-06	4.51e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—STK11—uterine cancer	7.67e-06	4.51e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—NRAS—uterine cancer	7.66e-06	4.51e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—NRAS—uterine cancer	7.66e-06	4.51e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—EP300—uterine cancer	7.56e-06	4.45e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—EP300—uterine cancer	7.56e-06	4.45e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—uterine cancer	7.49e-06	4.4e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—KRAS—uterine cancer	7.46e-06	4.39e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—NRAS—uterine cancer	7.31e-06	4.3e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—KRAS—uterine cancer	7.22e-06	4.24e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—KRAS—uterine cancer	7.22e-06	4.24e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—AKT1—uterine cancer	7.21e-06	4.24e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—HRAS—uterine cancer	7.16e-06	4.21e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KRAS—uterine cancer	7.12e-06	4.19e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—NRAS—uterine cancer	7.07e-06	4.16e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—NRAS—uterine cancer	7.07e-06	4.16e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTEN—uterine cancer	7.05e-06	4.15e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTEN—uterine cancer	6.86e-06	4.04e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—PIK3CA—uterine cancer	6.85e-06	4.03e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—KRAS—uterine cancer	6.82e-06	4.01e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ERBB2—uterine cancer	6.73e-06	3.96e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—EP300—uterine cancer	6.73e-06	3.96e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTEN—uterine cancer	6.64e-06	3.91e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTEN—uterine cancer	6.64e-06	3.91e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—PIK3CA—uterine cancer	6.63e-06	3.9e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—PIK3CA—uterine cancer	6.63e-06	3.9e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—KRAS—uterine cancer	6.59e-06	3.88e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—KRAS—uterine cancer	6.59e-06	3.88e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—EP300—uterine cancer	6.55e-06	3.85e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PIK3CA—uterine cancer	6.54e-06	3.85e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ERBB2—uterine cancer	6.51e-06	3.83e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ERBB2—uterine cancer	6.51e-06	3.83e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CXCL8—uterine cancer	6.38e-06	3.75e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—HRAS—uterine cancer	6.34e-06	3.73e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—EP300—uterine cancer	6.33e-06	3.72e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—EP300—uterine cancer	6.33e-06	3.72e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—uterine cancer	6.33e-06	3.72e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—AKT1—uterine cancer	6.32e-06	3.72e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—KRAS—uterine cancer	6.29e-06	3.7e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—PIK3CA—uterine cancer	6.26e-06	3.68e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CDKN1B—uterine cancer	6.23e-06	3.67e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CXCL8—uterine cancer	6.17e-06	3.63e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CXCL8—uterine cancer	6.17e-06	3.63e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—HRAS—uterine cancer	6.13e-06	3.61e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—HRAS—uterine cancer	6.13e-06	3.61e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—KRAS—uterine cancer	6.09e-06	3.58e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—KRAS—uterine cancer	6.09e-06	3.58e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—PIK3CA—uterine cancer	6.06e-06	3.56e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—PIK3CA—uterine cancer	6.06e-06	3.56e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HRAS—uterine cancer	6.05e-06	3.56e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CDKN1B—uterine cancer	6.03e-06	3.55e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CDKN1B—uterine cancer	6.03e-06	3.55e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTEN—uterine cancer	5.97e-06	3.51e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CTNNB1—uterine cancer	5.89e-06	3.46e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—HRAS—uterine cancer	5.79e-06	3.41e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PIK3CA—uterine cancer	5.78e-06	3.4e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—MTHFR—uterine cancer	5.76e-06	3.39e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTEN—uterine cancer	5.74e-06	3.38e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CTNNB1—uterine cancer	5.7e-06	3.35e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CTNNB1—uterine cancer	5.7e-06	3.35e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—EP300—uterine cancer	5.69e-06	3.35e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—HRAS—uterine cancer	5.6e-06	3.3e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—HRAS—uterine cancer	5.6e-06	3.3e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—AKT1—uterine cancer	5.6e-06	3.29e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PIK3CA—uterine cancer	5.59e-06	3.29e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PIK3CA—uterine cancer	5.59e-06	3.29e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTEN—uterine cancer	5.55e-06	3.27e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTEN—uterine cancer	5.55e-06	3.27e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EP300—uterine cancer	5.47e-06	3.22e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—AKT1—uterine cancer	5.42e-06	3.19e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—AKT1—uterine cancer	5.42e-06	3.19e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—HRAS—uterine cancer	5.35e-06	3.15e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—AKT1—uterine cancer	5.34e-06	3.14e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EP300—uterine cancer	5.29e-06	3.11e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EP300—uterine cancer	5.29e-06	3.11e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTEN—uterine cancer	5.2e-06	3.06e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—uterine cancer	5.18e-06	3.05e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—HRAS—uterine cancer	5.17e-06	3.04e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—HRAS—uterine cancer	5.17e-06	3.04e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NRAS—uterine cancer	5.12e-06	3.01e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—AKT1—uterine cancer	5.12e-06	3.01e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—uterine cancer	5.01e-06	2.95e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—uterine cancer	5.01e-06	2.95e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PIK3CA—uterine cancer	4.98e-06	2.93e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—EP300—uterine cancer	4.96e-06	2.92e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NRAS—uterine cancer	4.95e-06	2.91e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NRAS—uterine cancer	4.95e-06	2.91e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—AKT1—uterine cancer	4.95e-06	2.91e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—AKT1—uterine cancer	4.95e-06	2.91e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTEN—uterine cancer	4.9e-06	2.88e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PIK3CA—uterine cancer	4.84e-06	2.85e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—AKT1—uterine cancer	4.72e-06	2.78e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PIK3CA—uterine cancer	4.68e-06	2.75e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PIK3CA—uterine cancer	4.68e-06	2.75e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—EP300—uterine cancer	4.67e-06	2.75e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—AKT1—uterine cancer	4.57e-06	2.69e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—AKT1—uterine cancer	4.57e-06	2.69e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KRAS—uterine cancer	4.41e-06	2.59e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KRAS—uterine cancer	4.26e-06	2.51e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KRAS—uterine cancer	4.26e-06	2.51e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CA—uterine cancer	4.21e-06	2.48e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—AKT1—uterine cancer	4.06e-06	2.39e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CA—uterine cancer	4.05e-06	2.38e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—AKT1—uterine cancer	3.96e-06	2.33e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—uterine cancer	3.92e-06	2.3e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CA—uterine cancer	3.92e-06	2.3e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CA—uterine cancer	3.92e-06	2.3e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—AKT1—uterine cancer	3.83e-06	2.25e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—AKT1—uterine cancer	3.83e-06	2.25e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—uterine cancer	3.79e-06	2.23e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—uterine cancer	3.79e-06	2.23e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HRAS—uterine cancer	3.75e-06	2.2e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CA—uterine cancer	3.67e-06	2.16e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HRAS—uterine cancer	3.62e-06	2.13e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HRAS—uterine cancer	3.62e-06	2.13e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CA—uterine cancer	3.46e-06	2.03e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—AKT1—uterine cancer	3.44e-06	2.02e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AKT1—uterine cancer	3.31e-06	1.95e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTEN—uterine cancer	3.2e-06	1.88e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKT1—uterine cancer	3.2e-06	1.88e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKT1—uterine cancer	3.2e-06	1.88e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—EP300—uterine cancer	3.06e-06	1.8e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AKT1—uterine cancer	3e-06	1.76e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AKT1—uterine cancer	2.82e-06	1.66e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CA—uterine cancer	2.26e-06	1.33e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AKT1—uterine cancer	1.85e-06	1.09e-05	CbGpPWpGaD
